主页文献库搜索
A randomized double-blind study of the biological effects of celecoxib as a c...

Kim(E S),Hong(W K),Lee(J J),Mao(L),Morice(... J Clin Oncol 0000-00-00

...mos and 104 completed 6 mos of treatment. 3 pts experienced one grade 3 toxicity. No cardiac toxicities were observed. B...

Quality of life (QOL) changes in breast cancer patients participating in an a...

Bao(T),Shahverdi(K),Blackford(A L),Prowell... J Clin Oncol 0000-00-00

...MOS) sleep scale, MOS sexual function scale, and EuroQOL survey. Estrogens and inflammatory markers (interleukins 6 and ...

Nilotinib in advanced GIST: A retrospective analysis of nilotinib in compassi...

Montemurro(M),Schöffski(P),Reichardt(P),Ge... J Clin Oncol 0000-00-00

...Most pts had metastatic disease of gastric origin at initial diagnosis. KIT exon 11 mutations were most frequent. The me...

A phase I-II study of everolimus (RAD001) in combination with imatinib in pat...

Dumez(H),Reichard(P),Blay(J Y),Schöffski(P... J Clin Oncol 0000-00-00

10519 Background: Primary resistance to imatinib in pts with advanced GIST is uncommon but after durable benefit, most p...

Temozolomide (TMZ) 1 week on/1 week off as initial treatment for progressive ...

Soffietti(R),Rudà(R),Trevisan(E),Laguzzi(E... J Clin Oncol 0000-00-00

...mos and 12 mos, median PFS, quality of life and toxicity. The analysis of 1p/19q status by FISH and MGMT promoter methyl...

Gemcitabine for previously treated AIDS-related Kaposi's sarcoma: The Western...

Gregory(K M),Strother(R M),Pastakia(S),Wer... J Clin Oncol 0000-00-00

...mos. With a median follow-up of 5.1 mos, 2 pts were still receiving chemotherapy, 3 were lost to follow-up, and 18 compl...

Phase II study of oxaliplatin, capecitabine, and cetuximab in advanced hepato...

O'Neil(B H),Bernard(S A),Goldberg(R M),Moo... J Clin Oncol 0000-00-00

...mos (95% CI 2.3, 5.0).,The combination of capecitabine, oxaliplating and cetuximab is tolerable for most patients, altho...

Phase II feasibility trial incorporating bevacizumab into dose-dense doxorubi...

Miller(K D),O'Neill(A),Perez(E A),Seidman(... J Clin Oncol 0000-00-00

...mos. for Arm A and 10.8 mos. for Arm B; to date 52 pts in Arm A and 8 in Arm B have completed planned therapy. Median pr...

Different pancreatic cancer genomic risk prediction models derived from micro...

Mori(R),Collisson(E A),Hoffmann(A C),Kim(G... J Clin Oncol 0000-00-00

...mos.) and 6 from short-term (< 5 mos.) survivors. Multiple slide sections taken from each paraffin block were either mic...

Final results of the randomized phase II study of sequential docetaxel and ir...

Lind(P A),Gubanski(M),Johnsson(A),Fernebro... J Clin Oncol 0000-00-00

...mos and there was no statistical difference between the survival curves of the two study arms (log-rank test: P>0.05).,T...

上一页 678 679 680 681 682 683 684 685 686 下一页 682 / 共 704

联系地址

山东省济南市章丘区文博路2号

齐鲁师范学院 genelibs生信实验室

山东省济南市高新区舜华路750号

大学科技园北区F座4单元2楼

电话: 0531-88819269

微信公众号

关注微信订阅号,实时查看信息,关注医学生物学动态。


商务邮箱

E-mail: [email protected]